218 related articles for article (PubMed ID: 17081515)
1. Inverse agonism or neutral antagonism at G-protein coupled receptors: a medicinal chemistry challenge worth pursuing?
Greasley PJ; Clapham JC
Eur J Pharmacol; 2006 Dec; 553(1-3):1-9. PubMed ID: 17081515
[TBL] [Abstract][Full Text] [Related]
2. Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
Kenakin T
Mol Pharmacol; 2004 Jan; 65(1):2-11. PubMed ID: 14722230
[TBL] [Abstract][Full Text] [Related]
3. Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists.
Wieland K; Bongers G; Yamamoto Y; Hashimoto T; Yamatodani A; Menge WM; Timmerman H; Lovenberg TW; Leurs R
J Pharmacol Exp Ther; 2001 Dec; 299(3):908-14. PubMed ID: 11714875
[TBL] [Abstract][Full Text] [Related]
4. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
Hancock AA
Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
[TBL] [Abstract][Full Text] [Related]
5. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery.
Bond RA; Ijzerman AP
Trends Pharmacol Sci; 2006 Feb; 27(2):92-6. PubMed ID: 16406086
[TBL] [Abstract][Full Text] [Related]
6. G-protein-coupled receptor pharmacology: examining the edges between theory and proof.
Gilchrist A; Blackmer T
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):446-51. PubMed ID: 17659486
[TBL] [Abstract][Full Text] [Related]
7. Historical review: Negative efficacy and the constitutive activity of G-protein-coupled receptors.
Costa T; Cotecchia S
Trends Pharmacol Sci; 2005 Dec; 26(12):618-24. PubMed ID: 16260046
[TBL] [Abstract][Full Text] [Related]
8. Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective.
Milligan G
Mol Pharmacol; 2003 Dec; 64(6):1271-6. PubMed ID: 14645655
[TBL] [Abstract][Full Text] [Related]
9. Inverse agonists: tools to reveal ligand-specific conformations of G protein-coupled receptors.
Prather PL
Sci STKE; 2004 Jan; 2004(215):pe1. PubMed ID: 14722344
[TBL] [Abstract][Full Text] [Related]
10. Ghrelin receptor inverse agonists: identification of an active peptide core and its interaction epitopes on the receptor.
Holst B; Lang M; Brandt E; Bach A; Howard A; Frimurer TM; Beck-Sickinger A; Schwartz TW
Mol Pharmacol; 2006 Sep; 70(3):936-46. PubMed ID: 16798937
[TBL] [Abstract][Full Text] [Related]
11. Inverse agonism: more than reverting constitutively active receptor signaling.
Dupré DJ; Rola-Pleszczynski M; Stanková J
Biochem Cell Biol; 2004 Dec; 82(6):676-80. PubMed ID: 15674435
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis of inverse agonism in a G protein-coupled receptor.
Vilardaga JP; Steinmeyer R; Harms GS; Lohse MJ
Nat Chem Biol; 2005 Jun; 1(1):25-8. PubMed ID: 16407989
[TBL] [Abstract][Full Text] [Related]
13. Inverse agonism at beta-adrenergic receptors: therapeutic implications.
Gurdal H
Expert Rev Neurother; 2002 Mar; 2(2):261-9. PubMed ID: 19811007
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of inverse agonists for G-protein-coupled receptors.
Soudijn W; van Wijngaarden I; Ijzerman AP
Med Res Rev; 2005 Jul; 25(4):398-426. PubMed ID: 15816047
[TBL] [Abstract][Full Text] [Related]
15. The evasive nature of drug efficacy: implications for drug discovery.
Galandrin S; Oligny-Longpré G; Bouvier M
Trends Pharmacol Sci; 2007 Aug; 28(8):423-30. PubMed ID: 17659355
[TBL] [Abstract][Full Text] [Related]
16. "Phenotypic" pharmacology: the influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology.
Nelson CP; Challiss RA
Biochem Pharmacol; 2007 Mar; 73(6):737-51. PubMed ID: 17046719
[TBL] [Abstract][Full Text] [Related]
17. Constitutive activity and inverse agonism at the alpha1adrenoceptors.
Cotecchia S
Biochem Pharmacol; 2007 Apr; 73(8):1076-83. PubMed ID: 17125741
[TBL] [Abstract][Full Text] [Related]
18. Lack of receptor-selective effects of either RGS2, RGS3 or RGS4 on muscarinic M3- and gonadotropin-releasing hormone receptor-mediated signalling through G alpha q/11.
Karakoula A; Tovey SC; Brighton PJ; Willars GB
Eur J Pharmacol; 2008 Jun; 587(1-3):16-24. PubMed ID: 18457830
[TBL] [Abstract][Full Text] [Related]
19. Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors.
Berg KA; Harvey JA; Spampinato U; Clarke WP
Trends Pharmacol Sci; 2005 Dec; 26(12):625-30. PubMed ID: 16269190
[TBL] [Abstract][Full Text] [Related]
20. Subtleties in GPCR drug discovery: a medicinal chemistry perspective.
Fujioka M; Omori N
Drug Discov Today; 2012 Oct; 17(19-20):1133-8. PubMed ID: 22732182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
